Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Alpha-tocopheroloxyacetic acid - Veana Therapeutics

Next Previous
Drug Profile

Alpha-tocopheroloxyacetic acid - Veana Therapeutics

Alternative Names: 12-trimethyltridecyl) chroman-6-yloxy) acetic Acid; 261929-52-6; alpha-TEA; Oral Vimo-001; Oral Vimo-002; Oral Vimo-003; Oral Vimo-004; Oral Vimo-005; Vimo 001; Vimo 002; Vimo 003; Vimo 004; Vimo 005; Vimo-V001; VT-101; α-TEA - Veana Therapeutics

Latest Information Update: 22 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Veana Therapeutics
  • Developer Providence Health & Services; Veana Therapeutics
  • Class Antineoplastics; Cancer vaccines; Small molecules
  • Mechanism of Action Autophagy stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I HER2 positive breast cancer
  • Preclinical Cancer; Prostate cancer
  • Discontinued Carcinoma; Lymphoma; Sarcoma

Most Recent Events

  • 22 Sep 2022 Phase I development is still ongoing for Her2 positive Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT04120246)
  • 21 Sep 2022 Discontinued - Phase-I for Carcinoma (Metastatic disease) in USA (PO) before September 2022 (Veana Therapeutics pipeline, September 2022)
  • 21 Sep 2022 Discontinued - Phase-I for Lymphoma (Metastatic disease) in USA (PO) before September 2022 (Veana Therapeutics pipeline, September 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top